- In patients with rheumatoid arthritis (RA) in clinical remission (DAS28-CRP scores
Why this matters
- Findings do not support adoption of the MRI-guided treat-to-target strategy for disease activity remission and lack of radiographic progression.
- Randomized clinical trial of patients with RA in clinical remission (n=200) allocated to an MRI-guided vs a conventional treat-to-target strategy followed for 24 months in IMAGINE-RA.
- The coprimary outcomes were achievement of DAS28-CRP remission (DAS28-CRP
- Funding: AbbVie; others.
- No difference between the MRI group and the conventional group on the achievement of coprimary outcomes of clinical remission (85.3% vs 88.3%; P=.19) and absence of radiographic progression (66.2% vs 62.4%; P=.25).
- Serious adverse events were experienced by 17% of the MRI group vs 6% of the conventional group.
- Unblinded design.
- An imbalance in some baseline characteristics favored the conventional treat-to-target group.
- Generalizability was reduced because only patients receiving conventional synthetic DMARDs, not biologic DMARDs, were eligible for inclusion.